12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epodure: Interim Phase IIa data

Interim data from 4 ESRD patients with anemia who are on dialysis in an open-label, Israeli Phase IIa trial showed that a single treatment of 19-51 IU/kg/day subcutaneous Epodure maintained hemoglobin target levels of 9-11 g/dL...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >